Sensitivity of estimands in clinical trials with imperfect compliance

被引:2
|
作者
Chen, Heng [1 ]
Heitjan, Daniel F. [2 ,3 ]
机构
[1] Gilead Sci Inc, Biostat, Foster City, CA 94404 USA
[2] Southern Methodist Univ, Dept Stat Sci, Dallas, TX 75205 USA
[3] Univ Texas Southwestern Med Ctr, Peter ODonnell Jr Sch Publ Hlth, Dallas, TX 75390 USA
来源
关键词
complier average causal effect; intention-to-treat; noncompliance; randomization; sensitivity; PRINCIPAL STRATIFICATION; EPIDURAL ANALGESIA; IDENTIFICATION; INFERENCE; EFFICACY; BIAS;
D O I
10.1515/ijb-2022-0105
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical trials that are subject to noncompliance, the commonly used intention-to-treat estimand is valid as a causal effect of treatment assignment but is sensitive to the level of compliance. An alternative estimand, the complier average causal effect (CACE), measures the average effect of treatment received in the latent subset of subjects who would comply with either assigned treatment. Because the principal stratum of compliers can vary with the circumstances of the trial, CACE too depends on the compliance fraction. We propose a model in which an underlying latent proto-compliance interacts with trial characteristics to determine a subject's compliance behavior. When the latent compliance is independent of the individual treatment effect, the average causal effect is constant across compliance classes, and CACE is robust across trials and equal to the population average causal effect. We demonstrate the potential degree of sensitivity of CACE in a simulation study, an analysis of data from a trial of vitamin A supplementation in children, and a meta-analysis of trials of epidural analgesia in labor.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 50 条
  • [1] Response to comments on 'sensitivity of estimands in clinical trials with imperfect compliance'
    Chen, Heng
    Heitjan, Daniel F.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024,
  • [2] Comments on "sensitivity of estimands in clinical trials with imperfect compliance" by Chen and Heitjan
    Baker, Stuart G.
    Lindeman, Karen S.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2024,
  • [3] Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials
    Mehrotra, Devan V.
    Hemmings, Robert J.
    Russek-Cohen, Estelle
    CLINICAL TRIALS, 2016, 13 (04) : 456 - 458
  • [4] Estimands and Their Role in Clinical Trials
    Akacha, Mouna
    Bretz, Frank
    Ohlssen, David
    Rosenkranz, Gerd
    Schmidli, Heinz
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (03): : 268 - 271
  • [5] Estimands in diabetes clinical trials
    Min, Thinzar
    Bain, Stephen C.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (03): : 181 - 183
  • [6] Choosing Appropriate Estimands in Clinical Trials
    Ann-Kristin Leuchs
    Jörg Zinserling
    Andreas Brandt
    Dorothee Wirtz
    Norbert Benda
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 584 - 592
  • [7] Causal Inference and Estimands in Clinical Trials
    Lipkovich, Ilya
    Ratitch, Bohdana
    Mallinckrodt, Craig H.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 54 - 67
  • [8] Choosing Appropriate Estimands in Clinical Trials
    Leuchs, Ann-Kristin
    Zinserling, Joerg
    Brandt, Andreas
    Wirtz, Dorothee
    Benda, Norbert
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 584 - 592
  • [9] Estimands in clinical trials - broadening the perspective
    Akach, Mouna
    Bretz, Frank
    Ruberg, Stephen
    STATISTICS IN MEDICINE, 2017, 36 (01) : 5 - 19
  • [10] Estimands in clinical trials - a challenge to intention to treat?
    Day, Simon
    STATISTICS IN MEDICINE, 2017, 36 (01) : 3 - 4